当前位置： SCI文献检索 > Therapeutic Innovation & Regulatory Science期刊下所有文献 > Optimal Decision Criteria for the Study Design and Sample Size of a Biomarker-Driven Phase III Trial.

Optimal Decision Criteria for the Study Design and Sample Size of a Biomarker-Driven Phase III Trial.

Abstract：

BACKGROUND:The design and sample size of a phase III study for new medical technologies were historically determined within the framework of frequentist hypothesis testing. Recently, drug development using predictive biomarkers, which can predict efficacy based on the status of biomarkers, has attracted attention, and various study designs using predictive biomarkers have been suggested. Additionally, when choosing a study design, considering economic factors, such as the risk of development, expected revenue, and cost, is important. METHODS:Here, we propose a method to determine the optimal phase III design and sample size and judge whether the phase III study will be conducted using the expected net present value (eNPV). The eNPV is defined using the probability of success of the study calculated based on historical data, the revenue that will be obtained after the success of the phase III study, and the cost of the study. Decision procedures of the optimal phase III design and sample size considering historical data obtained up to the start of the phase III study were considered using numerical examples. RESULTS:Based on the numerical examples, the optimal study design and sample size depend on the mean treatment effect in the biomarker-positive and biomarker-negative populations obtained from historical data, the between-trial variance of response, the prevalence of the biomarker-positive population, and the threshold value of probability of success required to go to phase III study. CONCLUSIONS:Thus, the design and sample size of a biomarker-driven phase III study can be appropriately determined based on the eNPV.

journal_name

Ther Innov Regul Sci

journal_title

Therapeutic innovation & regulatory science

authors

Takazawa A,Morita S

doi

10.1007/s43441-020-00119-1

subject

Has Abstract

pub_date

2020-09-01 00:00:00

pages

1018-1034

issue

5

eissn

2168-4790

issn

2168-4804

pii

10.1007/s43441-020-00119-1

journal_volume

54

pub_type

杂志文章

相关文献

Therapeutic Innovation & Regulatory Science文献大全
  • phactMI Benchmarking Survey on Content Development and Inquiry Management.

    abstract：BACKGROUND:Medical information (MI) departments across pharmaceutical companies respond to medical inquiries about a company's products to healthcare providers, payors, patients, and caregivers. Responses provided are constructed to be relevant, accurate, scientifically balanced and delivered in a timely manner. Benchm...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00137-z

    authors： Byun J,Jong JA,Gangat A,Flowers T,Gazo A,Shah I

    更新日期：2020-11-01 00:00:00

  • Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation.

    abstract：:After nearly a decade of discussion, analysis, and development, the Medicines Adaptive Pathways to Patients (MAPPs) initiative is beginning to see acceptance from regulators, industry, patients, and payers, with the first live pilot project initiated under the guidance of the European Medicines Agency in 2014. Althoug...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479015618697

    authors： Schulthess D,Baird LG,Trusheim M,Unger TF,Lumpkin M,Hoos A,Garner S,Gavin P,Goldman M,Seigneuret N,Chlebus M,Van Baelen K,Bergstrom R,Hirsch G

    更新日期：2016-05-01 00:00:00

  • Implementing the Principle of the 3 Rs Through the Indian Pharmacopoeia.

    abstract：:Quality and safety tests are required for regulatory approval of drugs and pharmaceuticals in the country to guarantee minimum safety standards, and most of these tests include animal usage. In the case of biological medicines, these safety and quality tests have to be performed on a batch-to-batch basis and require a...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479015572371

    authors： Rastogi S,Kalaivani M,Bhatia AK,Prakash J,Singh GN

    更新日期：2015-09-01 00:00:00

  • Evaluation and Characterization of Health Economics and Outcomes Research in SAARC Nations.

    abstract：OBJECTIVE:To identify, evaluate, and characterize the variety, quality, and intent of the health economics and outcomes research studies being conducted in SAARC (South Asian Association for Regional Cooperation) nations. METHODS:Studies published in English language between 1990 and 2015 were retrieved from Medline d...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章,评审

    doi：10.1177/2168479017731583

    authors： Mehta M,Nerurkar R

    更新日期：2018-05-01 00:00:00

  • Evolving Clinical Data Strategies and Tactics in Response to Digital Transformation.

    abstract：BACKGROUND:Contending with a continuously expanding volume and variety of clinical data poses challenges and opportunities for the industry and clinical data management organizations. METHODS:Tufts CSDD conducted an online survey aimed at further quantifying and understanding the magnitude and impact that expanded dat...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00213-4

    authors： Harper B,Wilkinson M,Indupuri R,Rocchio S,Getz K

    更新日期：2020-09-14 00:00:00

  • Quantitative Extrapolation: An Approach to Validation of Adult Drug Efficacy in Pediatric Subjects.

    abstract：:Confirmation of efficacy in pediatric drug development has traditionally required large, fully powered efficacy studies that have proven to have major feasibility and ethical challenges. Extrapolation of efficacy in the framework provided by the US Food and Drug Administration and European Medicines Agency is an appro...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479013500286

    authors： Leil TA,Zee P,Suryawanshi S,Male C,Portman R

    更新日期：2013-09-01 00:00:00

  • Bowel Preparations for Colonoscopy: A Regulatory Perspective.

    abstract：:Agents indicated for cleansing of the colon as a preparation for colonoscopy (bowel preps) are among the most frequently prescribed drugs for otherwise healthy patients. Better bowel preparation has been shown to translate into higher adenoma detection rates. Therefore, safety and efficacy standards need to be high. C...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479015577868

    authors： Gottlieb K,Turner JR,Gillespie BS,Hussain F

    更新日期：2015-09-01 00:00:00

  • Risk Evaluation and Mitigation Strategies With Elements to Assure Safe Use: Alignment of the Goals With the Tools to Manage Risk.

    abstract：:The Food and Drug Administration Amendments Act of 2007 gave the FDA the authority to require drug sponsors to submit a risk evaluation and mitigation strategies (REMS) program for those medicines with serious risks such that failure to effectively manage these risks would tip the benefit-risk balance. As of August 8,...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479014527749

    authors： Cronin M,Berger S,Seligman PJ

    更新日期：2014-11-01 00:00:00

  • Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance.

    abstract：BACKGROUND:Safety data are continuously evaluated throughout the life cycle of a medical product to accurately assess and characterize the risks associated with the product. The knowledge about a medical product's safety profile continually evolves as safety data accumulate. METHODS:This paper discusses data sources a...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章,评审

    doi：10.1177/2168479017741112

    authors： Izem R,Sanchez-Kam M,Ma H,Zink R,Zhao Y

    更新日期：2018-03-01 00:00:00

  • A Practical Estimation Method for Analyzing Adverse Drug Reactions Using Data Mining.

    abstract：:This study aimed to determine the potentially severe chemical properties of drugs that can cause adverse drug reactions (ADRs) such as erythema multiforme (EM), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) by using a data mining method. The study data were extracted from the Adverse Event Repor...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/0092861512460759

    authors： Shirakuni Y,Okamoto K,Uejima E,Inui S,Takahara JI,Ohgaru T,Yamasaki H,Tian Y,Kawashita N,Inoue R,Yasunaga T,Takagi T

    更新日期：2013-03-01 00:00:00

  • Study Designs in Multi-arm Trials for Breast Cancer: A Systematic Literature Review of Major Journals.

    abstract：BACKGROUND:Several articles showed that statistical efficiency of multi-arm randomized clinical trials (RCTs) is much better than conventional two-arm RCTs. Multi-arm RCTs attract interest mainly when the experimental treatment regimen is not optimized or several pipelines under development exist. Breast cancer is a po...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00141-3

    authors： Nomura S,Miyauchi Y,Ajisawa Y,Isogaya K,Sozu T

    更新日期：2020-09-01 00:00:00

  • Labeling Standards for Biosimilar Products.

    abstract：:In 2010 Congress established a regulatory pathway for the approval of biosimilar products in the United States. FDA has embarked on developing the implementation framework for this pathway which includes creating guidance to assist biosimilar manufacturers in the development of these products. However, to date, the gu...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479013515249

    authors： Davis GC,Bowker GM

    更新日期：2014-05-01 00:00:00

  • Methods for Employing Information About Uncertainty of Ascertainment of Events in Clinical Trials.

    abstract：BACKGROUND:Uncertain ascertainment of events in clinical trials has been noted for decades. To correct possible bias, Clinical Endpoint Committees (CECs) have been employed as a critical element of trials to ensure consistent and high-quality endpoint evaluation, especially for cardiovascular endpoints. However, the ef...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00206-3

    authors： Chen Y,Lawrence J,Hung HMJ,Stockbridge N

    更新日期：2021-01-01 00:00:00

  • New Benchmarks Characterizing Growth in Protocol Design Complexity.

    abstract：:The Tufts Center for the Study of Drug Development and Medidata Solutions Inc analyzed data from 9737 protocols and 130,601 investigative site contracts associated with these protocols to derive updated benchmarks characterizing protocol complexity. The results of the study indicate that protocol design complexity con...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479017713039

    authors： Getz KA,Campo RA

    更新日期：2018-01-01 00:00:00

  • Strategic Shift of Statistical Review on Data Quality Assessment for New Drug Applications in China.

    abstract：:Data quality is critical for clinical trials to obtain robust conclusions about drug safety and efficacy evaluation. Effective data quality evaluation has been one of the major obstacles to new drug approvals in China, which hinders innovation in drug discovery and development ultimately. To improve the data quality s...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479018778528

    authors： Wang J,Wang G,Li M,Han J,Zeng X,Pan J,Yang J

    更新日期：2019-03-01 00:00:00

  • Investigating Rates of Food and Drug Administration Approvals and Guidances in Drug Development: A Structural Breakpoint/Cointegration Timeseries Analysis.

    abstract：BACKGROUND:The number of original and supplemental ANDAs, BLAs, NDAs, and Biosimilars FDA drug/biologic approvals (Approvals) has risen dramatically in the recent years, incidentally, so has the number of issued FDA guidances (Guidances). It is hypothesized that if the structures of the two timeseries are similar and/o...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00123-5

    authors： Daizadeh I

    更新日期：2020-09-01 00:00:00

  • Regulatory Issues of Voluntary Certification of Food Supplements in Russia.

    abstract：:When registering food supplements in Russia, restrictions on the labeling and consumer leaflet contents are tightly controlled by the regulatory agencies. Thus, misleading advertising is the most difficult problem with the turnover of these products if information in the commercials does not correspond to the informat...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章,评审

    doi：10.1007/s43441-019-00043-z

    authors： Lozda R

    更新日期：2020-01-01 00:00:00

  • Complex Generic Products: Insight of Current Regulatory Frameworks in US, EU and Canada and the Need of Harmonisation.

    abstract：:The regulatory agencies all over the world have defined the pathway and regulations for the approval of simple small-molecule generics. In addition, the agencies are striving to form perspicuous regulatory frameworks for the approval of biosimilars. In this view, there are no defined regulations for the approval of co...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章,评审

    doi：10.1007/s43441-020-00114-6

    authors： Lunawat S,Bhat K

    更新日期：2020-09-01 00:00:00

  • Expediting Drug Development: FDA's New Regenerative Medicine Advanced Therapy Designation.

    abstract：:In March 2017, the US FDA introduced the new Regenerative Medicine Advanced Therapy (RMAT) designation thus recognizing the enormous potential of these medicines and the need for efficient regulatory tools to accelerate their development and their commercial availability. The development of regenerative medicines is v...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479018779373

    authors： Vaggelas A,Seimetz D

    更新日期：2019-05-01 00:00:00

  • The Roles of Regulatory Science Research in Drug Development at the Pharmaceuticals and Medical Devices Agency of Japan.

    abstract：:Recently, it is becoming increasingly difficult to develop innovative drugs. Thus, the role of regulatory science research in drug development and postmarketing settings has become more important. In this article, the authors discuss the roles of regulatory science research at the Pharmaceuticals and Medical Devices A...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479012469950

    authors： Asahina Y,Tanaka A,Uyama Y,Kuramochi K,Maruyama H

    更新日期：2013-01-01 00:00:00

  • Product Registration in Developing Countries: A Proposal for an Integrated Regional Licensing System Among Countries in Regional Economic Blocs.

    abstract：:The product pipeline for diseases that disproportionately affect the developing world has considerably expanded over the last decade. Indeed, there are about 134 products for these diseases in the pipeline, including vaccines, drugs, diagnostics, microbicides, and vector control tools, and dozens of these products are...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479013478952

    authors： Saidu Y,De Angelis D,Aiolli S,Stefano G,Georges AM

    更新日期：2013-05-01 00:00:00

  • An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency.

    abstract：BACKGROUND:This study compared the timing, regulatory marketing authorization decisions, and the final labeling for products submitted to Swissmedic to those submitted to European Medicines Agency (EMA) and the US Food & Drug Administration (FDA). METHODS:The Centre for Innovation in Regulatory Science (CIRS) conducte...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479016655841

    authors： Dörr P,Wadworth A,Wang T,McAuslane N,Liberti L

    更新日期：2016-11-01 00:00:00

  • Regulatory Definitions and Good Pharmacovigilance Practices in Social Media: Challenges and Recommendations.

    abstract：:Social media presents new challenges to the biopharmaceutical industry for conducting pharmacovigilance activities. The authors reviewed worldwide regulatory guidance documents related to monitoring of adverse events posted on social media sites and identified gaps in current regulatory definitions for pharmacovigilan...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479015587362

    authors： Naik P,Umrath T,van Stekelenborg J,Ruben R,Abdul-Karim N,Boland R,Ibara M,Ekuta J,Washburn D,Stergiopoulos S

    更新日期：2015-11-01 00:00:00

  • The Competence and Willingness to Consent to Research Among Patients with Heroin Dependence.

    abstract：BACKGROUND:Substance abuse research can raise ethical concerns about the comprehension and decision-making capacities of participants with drug dependence. In this study, the competence and willingness to consent to research participation were examined among patients with heroin dependence. METHODS:Twenty patients wit...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00127-1

    authors： Zhao L,Shi H,Ying B,Li Q

    更新日期：2020-09-01 00:00:00

  • Patient Experience Data in US Food and Drug Administration (FDA) Regulatory Decision Making:: A Policy Process Perspective.

    abstract：BACKGROUND:The influence of patient advocates on FDA regulatory decision making has increased. Despite enhanced engagement with FDA, there remain challenges to achieving the regulatory goals of patients within FDA's regulatory framework. Gaps exist between patient advocates' knowledge of the agency's processes and FDA'...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1177/2168479017753390

    authors： Kuehn CM

    更新日期：2018-09-01 00:00:00

  • Regulatory Perspective of International Agencies for Development of Biosimilar Products (Monoclonal Antibodies): An Overview.

    abstract：:Biopharmaceutical medicines are complex molecules obtained from a living organism (plant or animal cells) and may contain components of a living organism using biotechnology. Biosimilars are closely similar to already approved biopharmaceutical products that could form a new generation of medicines that are available ...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章,评审

    doi：10.1007/s43441-020-00112-8

    authors： Sharma A,Khante S,Mahadik KR,Gaikwad VL

    更新日期：2020-09-01 00:00:00

  • Over-the-Counter Drugs: Regulatory Analysis of Warning Letters Between Fiscal Years 2015-2019.

    abstract：BACKGROUND:According to 21 Code of Federal Regulation (CFR) Part 211, Over-the-Counter (OTC) drug manufacturers must establish and follow current good manufacturing practices (cGMP) to produce quality products while meeting regulatory standards. The warning letters issued by the U.S. Food and Drug Administration (FDA) ...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00231-2

    authors： Bai HK,Ahearn JD,Bartlett MG

    更新日期：2020-10-23 00:00:00

  • Building a Better Approach for the Benefit of Patients: 10 Pillars to Strengthen Regulatory Review Systems Globally.

    abstract：:In the current pharmaceutical regulatory environment, patients continue to benefit from great advances in medical care. Sophisticated regulatory review systems have also evolved to ensure that safe and effective medicines are approved. However, these systems are not optimized in all countries. Gaps in individual regul...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-019-00055-9

    authors： O'Brien J,Lumsden RS,Diehl DH,Macdonald JC

    更新日期：2020-03-01 00:00:00

  • Sentiment of Media Coverage and Reputation of the Pharmaceutical Industry.

    abstract：BACKGROUND:Patients and health care professionals receive information about pharmaceutical companies through various sources, including but not limited to print media, social media, and electronic media. The objective of this research was to benchmark the sentiment of electronic newspaper media coverage between 2014 an...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-019-00048-8

    authors： Pampulevski V,Giaquinto JR,Rametta M,Toscani M,Barone J,Nadal JC

    更新日期：2020-01-01 00:00:00

  • Communicating Immunogenicity-Associated Risk in Current U.S. FDA Prescription Drug Labeling: A Systematic Evaluation.

    abstract：BACKGROUND:Communicating the clinical impact of immunogenicity in labeling is important for safe and effective use of certain prescription products. Current U.S. Food and Drug Administration (FDA) guidance does not provide comprehensive recommendations on the communication of clinical impact of immunogenicity in labeli...

    journal_title：Therapeutic innovation & regulatory science

    pub_type： 杂志文章

    doi：10.1007/s43441-020-00161-z

    authors： Guinn D,Madabushi R,Wang YM,Brodsky E,Zineh I,Maxfield K

    更新日期：2020-11-01 00:00:00